ストックスクリーナーアプリを入手
4.28
7.81%
0.31
Myriad Genetics Inc (MYGN) 最新ニュース
Statistics Show that Patients Want More Personalized Mental Health Care - KOIN.com
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics Inc stock (US62855J1043): Prolaris AI launch lifts focus - AD HOC NEWS
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock - Yahoo Finance UK
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - TradingView
MYGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Myriad Genetics’ Precise MRD Assay Data Presented at ASCO 2026 Shows Potential for Assessing Treatment Response and Monitoring Recurrence in Cancer Patients - geneonline.com
ASCO study: Myriad blood test flags higher cancer recurrence risk - Stock Titan
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans - Yahoo Finance
MYGN Technical Analysis | Trend, Signals & Chart Patterns | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics (MYGN) Unveils Innovative Prolaris + AI Test for Prostate Cancer - GuruFocus
Myriad Genetics launches Prolaris + AI prostate cancer test - Investing.com UK
Myriad Genetics launches Prolaris + AI prostate cancer test By Investing.com - Investing.com Nigeria
Myriad Genetics Launches Prolaris® + AI - TradingView
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) - marketscreener.com
Myriad Genetics Launches Prolaris Plus AI Test Combining Genomics And Digital Pathology Artificial Intelligence - marketscreener.com
MYGN Technical Analysis & Stock Price Forecast - Intellectia AI
Myriad Genetics (MYGN) price target decreased by 11.49% to 6.35 - MSN
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN) - MSN
Myriad Genetics | 5/22/26 - ktnv.com
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks - simplywall.st
Myriad Genetics executives to speak at SOPHiA GENETICS event, spotlighting industry partnerships - Traders Union
‘American Idol’ Star Speaks Out on Health Issues 17 Years After Show Appearance - Parade
Myriad Genetics in record sell-off after Q1 miss - MSN
Stocks With 20% Upside: Dollar Tree, Myriad Genetics, Antero Resources AnalysisNews and Statistics - IndexBox
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by Analysts - MarketBeat
Myriad Genetics, Inc. $MYGN Shares Acquired by Vanguard Group Inc. - MarketBeat
Jackie Tohn joins Myriad Genetics in campaign to expand hereditary cancer test awareness - Traders Union
Myriad Genetics, Inc.Common Stock (NQ: MYGN - FinancialContent
Myriad Genetics and actress Jackie Tohn promote hereditary cancer testing after her BRCA1 gene discovery. - Pluang
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life - markets.businessinsider.com
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing Awareness - Quiver Quantitative
Insider Buying: Paul Bisaro Acquires Shares of Myriad Genetics I - GuruFocus
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Myriad Genetics director Paul Bisaro buys $27,637 in stock By Investing.com - Investing.com Australia
Myriad Genetics director Paul Bisaro buys $27,637 in stock - Investing.com UK
Paul Bisaro (NASDAQ: MYGN) adds 7,500 Myriad Genetics shares - Stock Titan
Myriad Genetics Inc stock (US62855J1043): shares react to Q1 2025 results and updated 2025 guidance - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Myriad Genetics expands access to MyChoice Test for prostate cancer patients in Japan - SelectScience
Myriad Genetics unveils ultra-sensitive MRD testing focus at Tokyo oncology summit - Traders Union
1.39%
0.25%
大文字化:
|
ボリューム (24 時間):